Cbl c (CBLC) Rabbit Polyclonal Antibody

CAT#: AP07527PU-N

Cbl c (CBLC) rabbit polyclonal antibody, Aff - Purified



Need it in bulk or conjugated?
Get a free quote

CNY 6,116.00


货期*
5周

规格
    • 50 ug

Product images

Specifications

Product Data
Applications ELISA, IF, IHC, IP, WB
Recommend Dilution ELISA: 1/10000 - 1/50000.
Immunofluorescence.
Immunohistochemistry on Paraffin Sections: 5 µg/ml.
Immunoprecipitation.
Western Blot: 1/500 - 1/3000.
Reactivity Human
Host Rabbit
Clonality Polyclonal
Immunogen Synthetic peptide - KLH conjugated corresponding to amino acids 444-458 of Human Cbl-c.
Specificity This antibody recognizes RNF57/CBLC.
Formulation 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 with 0.01% (w/v) Sodium Azide.
State: Aff - Purified
State: Liquid purified Ig fraction.
Concentration lot specific
Purification Immunoaffinity Chromatography.
Conjugation Unconjugated
Storage Condition Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Gene Name Cbl proto-oncogene C
Background Cbl-c is also known as signal transduction protein CBL-C, SH3-binding protein CBL-C, CBL-3, and RING finger protein 57. Cbl proteins are a family of ubiquitin protein ligases (E3s) that negatively regulate signaling by targeting activated tyrosine kinases for degradation. Cbl-c (a.k.a. Cbl-3) is the most recently cloned member of the Cbl proteins and is expressed only in epithelial cells (the other Cbl proteins are ubiquitously expressed). Cbl-c, like the other mammalian Cbl proteins, can ubiquitinate the activated EGFR and target it for degradation. Cbl-c knock out mice show no obvious phenotype. Thus, the physiological role of Cbl-c is not known.
Synonyms CBL3, CBL-C, CBL-3, RING finger protein 57
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...